Article | January 1, 2022

Do Not Let HCPs Delay Your Biologics Route To Market

Source: Cytiva
GettyImages-1264101698-lab-research-scientist

The stakes are high in biologics development, especially in host cell protein (HCP) analysis. Get it wrong and it could delay your development cycle. See how optimizing your HCP assays can smooth your route to market.

In this article, review Chinese hamster ovary (CHO) cells, the challenge of analyzing HCPs, analyzing HCPs in biosimilars, and how to determine which HCP ELISA coverage assay to use.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online